JPRN-UMIN000050515招募中Unknown
IVOlumab Re-adminisTration for UnResectable/recurreNt gaStric cancer - NIVO-RETURNS
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with multiple cancers requiring systemic therapy excluding hormonal therapy. 2) Patients who are inappropriate for re-administration of nivolumab by the treating physician due to serious irAEs in previous therapy including anti-PD-1/PD-L1 antibodies. Patients with endocrine abnormalities and who can be re-administered nivolmab with hormone replacement can be enrolled. 3) Patients receiving continuous systemic administration of steroids or immunosuppressive agents with a prednisone equivalent of more than 10 mg/day (or equivalent dose) 4) Patients who are inappropriate for enrollment in this study by the treating physician.
研究者
相似试验
招募中
不适用
INFORM Registry INdividualized Therapy FOr Relapsed Malignancies in ChildhoodDRKS00007623Deutsches Krebsforschungszentrum / Universitätsklinikum Heidelberg10,000
进行中（未招募）
1 期
An open label, Aclasta, re-treatment of relapsed patients with Paget´s disease of bone who participated in the CZOL446K2304 and CZOL446K2305 Core Registration studies - NATreatment of Paget´s disease of the boneMedDRA version: 9.1Level: LLTClassification code 10033363Term: Paget's disease of boneEUCTR2008-002898-12-BEovartis Pharma Services AG30
进行中（未招募）
不适用
An open label, Aclasta, re-treatment of relapsed patients with Paget´s disease of bone who participated in the CZOL446K2304 and CZOL446K2305 Core Registration studies - NAEUCTR2008-002898-12-GBovartis Pharma Services AG30
进行中（未招募）
1 期
Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigatorDisease corresponding to the Novartis-sponsored study the patient will be transitioning fromEUCTR2012-004707-12-NLovartis Pharma Services AG13
已完成
4 期
An open-label, multi-center everolimus roll-over protocol for patients who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued everolimus treatmentadvanced carcinoid10014713NL-OMON38738ovartis1